As of 2026-09-10, the EV/EBITDA ratio of Enanta Pharmaceuticals Inc (ENTA) is -8.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ENTA's latest enterprise value is 477.98 mil USD. ENTA's TTM EBITDA according to its financial statements is -53.82 mil USD. Dividing these 2 quantities gives us the above ENTA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.6x - 15.5x | 12.8x |
| Forward P/E multiples | 11.8x - 17.2x | 14.6x |
| Fair Price | (25.11) - (31.85) | (28.51) |
| Upside | -289.6% - -340.5% | -315.3% |
| Date | EV/EBITDA |
| 2026-09-08 | -9.02 |
| 2026-09-04 | -9.34 |
| 2026-09-03 | -9.30 |
| 2026-09-02 | -9.34 |
| 2026-09-01 | -9.03 |
| 2026-08-31 | -8.93 |
| 2026-08-28 | -9.08 |
| 2026-08-27 | -9.18 |
| 2026-08-26 | -9.37 |
| 2026-08-25 | -9.34 |
| 2026-08-24 | -9.35 |
| 2026-08-21 | -9.01 |
| 2026-08-20 | -8.82 |
| 2026-08-19 | -9.03 |
| 2026-08-18 | -8.91 |
| 2026-08-17 | -8.66 |
| 2026-08-14 | -8.84 |
| 2026-08-13 | -8.99 |
| 2026-08-12 | -9.02 |
| 2026-08-11 | -9.03 |
| 2026-08-10 | -9.19 |
| 2026-08-07 | -9.17 |
| 2026-08-06 | -8.94 |
| 2026-08-05 | -8.87 |
| 2026-08-04 | -8.92 |
| 2026-08-03 | -8.72 |
| 2026-07-31 | -8.54 |
| 2026-07-30 | -8.75 |
| 2026-07-29 | -8.45 |
| 2026-07-28 | -8.54 |
| 2026-07-27 | -8.61 |
| 2026-07-24 | -8.63 |
| 2026-07-23 | -8.72 |
| 2026-07-22 | -8.78 |
| 2026-07-21 | -8.98 |
| 2026-07-20 | -8.84 |
| 2026-07-17 | -9.15 |
| 2026-07-16 | -8.85 |
| 2026-07-15 | -8.88 |
| 2026-07-14 | -8.81 |
| 2026-07-13 | -9.10 |
| 2026-07-10 | -9.13 |
| 2026-07-09 | -9.43 |
| 2026-07-08 | -9.56 |
| 2026-07-07 | -9.43 |
| 2026-07-06 | -9.57 |
| 2026-07-02 | -9.89 |
| 2026-07-01 | -9.71 |
| 2026-06-30 | -9.61 |
| 2026-06-29 | -9.57 |